CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, ...
Gvoke (glucagon) is a prescription drug that’s used to treat severely low blood sugar in certain people with diabetes. Gvoke comes as a liquid solution that’s given as an injection under the skin.
Credit: Getty Images. The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older. The Food and Drug Administration ...
The new Gvoke Kit formulation is available as a 1mg/0.2mL single-dose vial and syringe kit. Gvoke ® Kit is now available for the treatment of severe hypoglycemia in adult and pediatric patients with ...
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic patients ...
First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback